VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

A substitute specification along with the claims is submitted under 37 C.F.R. §1.125(a) since the top of each page of the original specification and claims was missing sections due to a two-hole punch. No new matter was added to the specification.

IN THE CLAIMS:

Please substitute claim 1 for the pending claim having the same claim number.

1. (Amended) A method for producing extended-release tablets comprising the steps of: mixing **a therapeutically effective amount of L-arginine [arginine]** with a sustained release matrix; and compressing said mixture to form tablets.

Please substitute claim 2 for the pending claim having the same claim number.

2. (Amended) The method of claim 1, wherein said L-arginine is selected from the group consisting of L-arginine **hydrochloride [hydrochlorie]**, pharmacologically acceptable L-arginine salts, and mixtures thereof.

Please substitute claim 13 for the pending claim having the same claim number.

13. (Amended) A composition comprised of **a therapeutically effective amount of L-arginine [arginine]**; and a sustained release polymeric matrix.

Please substitute claim 14 for the pending claim having the same claim number.

14. (Amended) The composition of claim 13, further including a nitrate.[,]

Please substitute claim 16 for the pending claim having the same claim number.

16. (Amended) An extended-release pharmaceutical tablet comprised of a sustained release matrix and **a therapeutically effective amount of L-arginine [arginine]**.